Progressive Multiple Sclerosis (MS) and Paraneoplastic CNS Disorders Gait Changes

Overview

Información sobre este estudio

The purpose of this study is to longitudinally measure cognitive performance in patients with multiple sclerosis and progressive immune-mediated neurodegenerative disorders in order to determine the rate of progression, and to establish quantitative functional biomarkers that can be used to measure treatment effectiveness in therapy trials directly targeting progressive immune-mediated neurodegeneration.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria:

Multiple Sclerosis

  • Diagnosed with multiple sclerosis according to the 2017 revised McDonald criteria.
  • Age ≥18 years.

 Physician determined disease progression

  • Patient must be able to walk without a walker for the motion tests (e.g. 25 ft walk)
  • Patient must be enrolled in IRB#08-007846 and actively participating in sample collections.
  • Patient must agree to the lumbar puncture and skin biopsy components of IRB#08-007846.

Progressive Immune-Mediated Neurodegenerative Disorder

  • Age ≥ 18 years.
  • Physician determined disease progression
  • Gait disorder is primarily associated with a seropositive autoimmune CNS disorder.
  • Patient must be able to walk without a walker for the motion tests (e.g. 25 ft walk).
  • Patient must be enrolled in IRB#08-007846 and actively participating in sample collections.
  • Patient must agree to the lumbar puncture and skin biopsy components of IRB#08-007846.

Exclusion Criteria: 

Multiple Sclerosis

  • Unable to have annual clinical MRI.

Progressive Immune-Mediated Neurodegenerative Disorder

  • Unable to have annual clinical MRI.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 11/22/23. Questions regarding updates should be directed to the study team contact.

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus Contacto

Rochester, Minn.

Investigador principal de Mayo Clinic

Sean Pittock, M.D.

Abierto para la inscripción

Contact information:

Center for Multiple Sclerosis and Autoimmune Neurology

DLCMSANResCoor@mayo.edu

More information

Publicaciones

Publications are currently not available
.
CLS-20548776

Mayo Clinic Footer